Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.
The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as age-related macular degeneration (AMD).
AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.
A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.
This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.
Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.
The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.
Dr de Cogan said: “The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.
“Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments.
“The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.
“We believe this is going to be very important in terms of empowering of patients and reducing the cost of treatment to the NHS.”
The Latest on: Age-related macular degeneration
- Novartis heart drug success opens up new care option on June 25, 2017 at 4:57 am
The heart drug news comes just two days after Novartis reported positive results with another experimental drug for neovascular age-related macular degeneration, a leading cause of vision loss. […]
- Hallelujah! Minister’s sight saved after chance visit to optician on June 25, 2017 at 3:21 am
Rev Barrie Hirst from Ruskington has credited his local Vision Express store for saving his sight after a crucial referral showed he had age-related macular degeneration (AMD). After a routine eye test at Vision Express Sleaford nearly 10 years ago ... […]
- ‘Vision Van’ drives positive change for macular disease burden, offering free eye tests for all in Wrexham on June 25, 2017 at 2:28 am
... city was identified as having almost a quarter of residents aged over 60, a significant risk group for age-related macular degeneration (AMD). The most common form of sight loss in the UK, AMD currently affects more than 600,000 people in the UK ... […]
- Local healthcare professionals give their best advice for optical disease prevention on June 24, 2017 at 10:20 pm
"As it progresses it causes permanent central vision loss." Macular degeneration, an age-related eye disease, has been linked to sun exposure and smoking. There are things people can do on their own to help prevent it, like wearing a hat and sunglasses ... […]
- Pioneering new Cyprus eye research for better vision on June 24, 2017 at 12:06 am
Ophthalmologist, Dr Tasos Georgiou explains age-related macular degeneration and discusses pioneering research under his supervision to combat the disease. How serious a condition is age-related macular degeneration? Firstly it should be mentioned that the ... […]
via Google News and Bing News